# Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)

> **NCT07246590** · PHASE3 · RECRUITING · sponsor: **Verrica Pharmaceuticals Inc.** · enrollment: 300 (estimated)

## Conditions studied

- Common Warts
- Common Warts (Verruca Vulgaris)
- Human Papilloma Virus (HPV)
- Warts

## Interventions

- **COMBINATION_PRODUCT:** VP-102
- **COMBINATION_PRODUCT:** Vehicle

## Key facts

- **NCT ID:** NCT07246590
- **Lead sponsor:** Verrica Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-17
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-01-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07246590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07246590, "Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07246590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*